Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Localized prostate cancer: Testosterone therapy is safe in appropriate patients after definitive treatment

Key clinical point: Testosterone therapy is not associated with increased risks of biochemical recurrence, prostate cancer-specific mortality, or all-cause mortality after surgery or radiation for localized prostate cancer.

Major finding: No differences in biochemical recurrence, prostate cancer-specific mortality, or overall mortality after radical prostatectomy (hazard ratio [HR], 1.07 [P = .59]; HR, 0.72 [P = .43]; and HR, 1.11 [P = .43], respectively) or radiation therapy (HR, 1.07 [P = .45]; HR, 1.02 [P = .95]; and HR, 1.02 [P = .86], respectively) was observed between testosterone users and nonusers.

Study details: The findings are based on an ethnically diverse population-based study of nearly 70,000 U.S. veterans.

Disclosures: This study was supported by the National Institutes of Health. The authors declared no conflicts of interest.

Citation:

Sarkar RR et al. Prostate Cancer Prostatic Dis. 2020 Jun 8. doi: 10.1038/s41391-020-0241-3.